Home›Research›Compare›AICAR vs Tirzepatide
Peptide ComparisonAICAR vs Tirzepatide
Both are Metabolic peptides.
Tirzepatide
Mounjaro
Half-life: ~5 days (once-weekly dosing)
536 providers listed
Tirzepatide is FDA-approved, while AICAR is investigational — the clearest structural difference between them.
AICAR
Evidence
Half-life
—
Tirzepatide
Evidence
Half-life
~5 days (once-weekly dosing)
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | Tirzepatide |
| Further along in FDA review | Tirzepatide |
| Lower typical price per mg | AICAR |
| More provider options (3 vs 536) | Tirzepatide |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
AICAR
Tirzepatide
AICAR
Targeting AMPK Networks for Male Reproductive Health: Mechanisms and Emerging Therapies.
Thapsigargin-induced autophagic flux impairment and inflammation are potentiated by CLN3 deficiency and allev…
The AMPK-PGC-1α-SIRT3 axis mediates mitochondrial metabolic dysfunction and neuronal senescence induced by Al…
Berberine Regulates Hepatic Fatty Acid Metabolism via AMPK/SIRT1/PGC-1α Pathway.
+8 more
Tirzepatide
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)
Tirzepatide Once Weekly for the Treatment of Obesity
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Targeting Inflammation and Fibrosis in Lipedema: The Potential Role of Glucagon-like Peptide-1 Receptor Agoni…
+9 more
About AICAR
Converted intracellularly to ZMP, a potent AMPK activator. AMPK activation increases fatty acid oxidation, glucose uptake, and mitochondrial biogenesis — the same metabolic pathways activated by sustained aerobic exercise.
About Tirzepatide
Tirzepatide is a dual agonist of both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP receptor activation adds a complementary mechanism to GLP-1 agonism — enhancing insulin secretion, reducing glucagon, and modulating adipose tissue metabolism independently of GLP-1 pathways. The combination produces greater average weight reduction in clinical trials than selective GLP-1 agonists at comparable doses.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
AICAR
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
Tirzepatide
Risk of thyroid C-cell tumors (dose- and duration-dependent in rodents; human relevance undetermined).
Source: FDA label
FDA prescribing protocols track HbA1c and fasting glucose for glycemic response, calcitonin for thyroid C-cell risk (black box warning), and lipase for pancreatitis screening. Baseline renal and hepatic panels are standard.
AICAR
Tirzepatide
Where to source these peptides
AICAR
3 listed
Browse directory →
Providers offeringTirzepatide
536 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Metabolic Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated July 27, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). AICAR vs Tirzepatide — Per-mg Price Comparison. Retrieved July 29, 2026, from https://peptidebase.io/peptides/compare/aicar/tirzepatide